These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 28738955

  • 1. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
    Fitzgerald TL, Mosquera C, Lea CS, McMullen M.
    Am Surg; 2017 Jul 01; 83(7):799-803. PubMed ID: 28738955
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y, Wang YF, Tan BB, Er LM, Zhao Q, Fan LQ, Zhang ZD, Liu Y.
    Zhonghua Zhong Liu Za Zhi; 2020 May 23; 42(5):426-431. PubMed ID: 32482035
    [Abstract] [Full Text] [Related]

  • 4. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M, Čačev T, Catela Ivković T, Marout J, Ulamec M, Zjačić-Rotkvić V, Kapitanović S.
    Mol Cell Endocrinol; 2016 Apr 15; 425():61-8. PubMed ID: 26805636
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C, Ha SY, Kim ST, Kim HC, Heo JS, Park YS, Lauwers G, Lee J, Kim KM.
    Oncotarget; 2016 Jan 26; 7(4):4024-35. PubMed ID: 26684240
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
    Grillo F, Albertelli M, Brisigotti MP, Borra T, Boschetti M, Fiocca R, Ferone D, Mastracci L.
    Neuroendocrinology; 2016 Jan 26; 103(5):452-9. PubMed ID: 26337010
    [Abstract] [Full Text] [Related]

  • 9. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
    Alvarado-Cabrero I, de Anda-González J, Hernández-Hernández B, Mantilla-Morales A, Valencia-Cedillo R, Medrano-Guzmán R.
    Rev Gastroenterol Mex; 2012 Jan 26; 77(4):174-80. PubMed ID: 23142406
    [Abstract] [Full Text] [Related]

  • 10. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
    Barrea L, Altieri B, Muscogiuri G, Laudisio D, Annunziata G, Colao A, Faggiano A, Savastano S.
    Nutrients; 2018 Dec 01; 10(12):. PubMed ID: 30513732
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.
    Martin JA, Warner RRP, Aronson A, Wisnivesky JP, Kim MK.
    Pancreas; 2017 Oct 01; 46(9):1214-1218. PubMed ID: 28902794
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chou WC, Chen YY.
    Asia Pac J Clin Oncol; 2016 Dec 01; 12(4):396-402. PubMed ID: 27357443
    [Abstract] [Full Text] [Related]

  • 18. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A, Thomassen I, van Gestel YRBM, van der Bilt JDW, Haak HR, de Hingh IHJT, Lemmens VEPP.
    Ann Surg Oncol; 2017 Aug 01; 24(8):2199-2205. PubMed ID: 28204963
    [Abstract] [Full Text] [Related]

  • 19. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
    Baptiste GG, Postlewait LM, Ethun CG, Le N, McInnis MR, Russell MC, Winer JH, Kooby DA, Staley CA, Maithel SK, Cardona K.
    J Surg Oncol; 2016 Aug 01; 114(2):163-9. PubMed ID: 27157897
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.